Phase III clinical trial - Appareil pulmonaire

This is a global, multicenter, randomized, active-controlled, open-label Phase 3 study designed to evaluate the;efficacy, safety, and pharmacokinetics (PK) of DS-1062a versus docetaxel in subjects with advanced or;metastatic NSCLC without actionable genomic alterations (ie, alterations in genes with approved therapies, such;as EGFR, ALK, ROS1, NTRK, BRAF, or other actionable driver oncogenes) and who have been previously;treated with platinum-based chemotherapy and a-PD-1/a-PD-L1 monoclonal antibody, either in combination or;sequentially. Patients who received a-PD-1/a-PD-L1 monoclonal antibody as frontline therapy may have;received the combination of platinum-based chemotherapy and a-PD-1/a-PD-L1 monoclonal antibody in the;second line setting.